Beranda › Miopati › Pennsylvania › Pittsburgh
Uji klinis Miopati di Pittsburgh, PA
3 studi untuk Miopati mencari peserta di lokasi sekitar Pittsburgh (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Menerima pesertaFase 2/3
- UPMC Children's Hospital of Pittsburgh - Accepting Juvenile Patients, Pittsburgh
- UPMC Arthritis and Autoimmunity Center - Accepting Adult Patients, Pittsburgh
Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy
Menerima pesertaFase 2
- University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology, Pittsburgh
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Menerima pesertaFase 3
- UPMC Arthritis and Autoimmunity Center, Falk Clinic, Pittsburgh
- UPMC Montefiore Clinical and Translational Research Center (CTRC), Pittsburgh
- UPMC Presbyterian Shadyside Hospital, Pittsburgh
Uji klinis Miopati di kota lain
- Durham, NC10 studi
- New York City, NY6 studi
- Chicago, IL6 studi
- Boston, MA6 studi
- Houston, TX5 studi
- Cedar Rapids, IA4 studi
- Miami, FL4 studi
- Orange, CA3 studi
- Dallas, TX3 studi
- Charlotte, NC3 studi
- Ann Arbor, MI3 studi
- Gainesville, FL3 studi
Studi lain di Pittsburgh
- Kanker Paru Non-Sel Kecil48 studi
- Kanker (semua jenis)41 studi
- Kanker Payudara39 studi
- Kanker Kolorektal32 studi
- Kanker Metastatik31 studi
- Melanoma31 studi
- Kanker Ovarium30 studi
- Kanker Endometrium23 studi
- Kanker Paru23 studi
- Kanker Prostat23 studi
- Stroke22 studi
- Karsinoma Sel Skuamosa Kepala dan Leher22 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.